First-line lenvatinib plus pembrolizumab treatment across non-clear cell renal cell carcinomas: Results of the phase 2 KEYNOTE-B61 study.

被引：0
|
作者：
Lee, Chung-Han
Gurney, Howard
Atduev, Vagif
Suarez, Cristina
Duran, Miguel A. Climent
Pook, David William
Tomczak, Piotr
Barthelemy, Philippe
Lee, Jae-Lyun
Nalbandian, Taron
Stus, Viktor
Ferguson, Thomas
Wiechno, Pawel
Gokmen, Erhan
Lacombe, Louis
Gedye, Craig
Burgents, Joseph
Sharma, Manish
Peng, Xiang
Albiges, Laurence
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Macquarie Univ, Sydney, NSW, Australia
[3] Fed Med Biol Agcy, Volga Dist Med Ctr, Nizhnii Novgorod, Russia
[4] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Med Oncol, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain
[5] Inst Valenciano Oncol, Valencia, Spain
[6] Monash Hlth, Melbourne, Vic, Australia
[7] Poznan Univ Med Sci, Poznan, Poland
[8] Inst Cancerol Strasbourg Europe, Strasbourg, France
[9] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[10] Reg Canc Ctr, Kharkiv, Ukraine
[11] Dnipro State Med Univ, Dnipro, Ukraine
[12] Fiona Stanley Hosp, Perth, WA, Australia
[13] Inst Marii Sklodowskiej Curie, Oncol Ctr, Warsaw, Poland
[14] Ege Univ, Fac Med, Izmir, Turkiye
[15] CHU Quebec, Ctr Rech, Quebec City, PQ, Canada
[16] Univ Newcastle, Callaghan, NSW, Australia
[17] Merck & Co Inc, Rahway, NJ 07065 USA
[18] Gustave Roussy, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4518
引用
收藏
页数：1
相关论文
共 50 条
  • [1] First-line pembrolizumab plus lenvatinib for non-clear cell renal carcinomas (nccRCC): Extended follow-up of the phase 2 KEYNOTE-B61 study.
    Voss, Martin H.
    Gurney, Howard
    Atduev, Vagif
    Suarez, Cristina
    Climent, Miguel Angel
    Pook, David William
    Tomczak, Piotr
    Barthelemy, Philippe
    Lee, Jae-Lyun
    Nalbandian, Taron
    Stus, Viktor
    Ferguson, Thomas
    Wiechno, Pawel
    Gokmen, Erhan
    Lacombe, Louis
    Gedye, Craig
    Burgents, Joseph E.
    Sharma, Manish
    Cornell, Jerry
    Albiges, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 2 - 2
  • [2] Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) plus lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC)
    Albiges, L.
    Gurney, H. P.
    Atduev, V.
    Suarez, C.
    Climent Duran, M. A.
    Pook, D.
    Tomczak, P.
    Barthelemy, P.
    Lee, J-L.
    Nalbandian, T.
    Stus, V.
    Ferguson, T.
    Wiechno, P.
    Gokmen, E.
    Lacombe, L.
    Gedye, C.
    Perini, R.
    Sharma, M.
    Li, C.
    Lee, C-H.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1204 - S1204
  • [3] KEYNOTE-B61: Open-label phase 2 study of pembrolizumab in combination with lenvatinib as first-line treatment for non-clear cell renal cell carcinoma (nccRCC).
    Lee, Chung-Han
    Li, Chenxiang
    Perini, Rodolfo F.
    Hoehn, Daniela
    Albiges, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61) a single-arm, multicentre, phase 2 trial 
    Albiges, Laurence
    Gurney, Howard
    Atduev, Vagif
    Suarez, Cristina
    Climent, Miguel A.
    Pook, David
    Tomczak, Piotr
    Barthelemy, Philippe
    Lee, Jae Lyun
    Stus, Viktor
    Ferguson, Thomas
    Wiechno, Pawel
    Gokmen, Erhan
    Lacombe, Louis
    Gedye, Craig
    Perini, Rodolfo F.
    Sharma, Manish
    Peng, Xiang
    Lee, Chung-Han
    LANCET ONCOLOGY, 2023, 24 (08): : 881 - 891
  • [5] PHASE 3 STUDY OF PEMBROLIZUMAB plus BELZUTIFAN plus LENVATINIB OR PEMBROLIZUMAB/QUAVONLIMAB plus LENVATINIB VERSUS PEMBROLIZUMAB plus LENVATINIB AS FIRST-LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMA
    Choueiri, Toni
    Plimack, Elizabeth
    Powles, Thomas
    Voss, Martin
    Gurney, Howard
    Silverman, Rachel
    Perini, Rodolfo
    Rodriguez-Lopez, Karla
    Rini, Brian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A447 - A447
  • [6] First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC
    Romero, Diana
    NATURE REVIEWS CLINICAL ONCOLOGY, 2023, 20 (10) : 661 - 661
  • [7] First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC
    Diana Romero
    Nature Reviews Clinical Oncology, 2023, 20 : 661 - 661
  • [8] Phase 3 study of first-line treatment with pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib for advanced renal cell carcinoma (RCC).
    Choueiri, Toni K.
    Plimack, Elizabeth R.
    Powles, Thomas
    Voss, Martin H.
    Gurney, Howard
    Silverman, Rachel Kloss
    Perini, Rodolfo F.
    Rodriguez-Lopez, Karla
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [9] First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B.
    McDermott, David F.
    Lee, Jae-Lyun
    Ziobro, Marek
    Gafanov, Rustem Airatovich
    Matveev, Vsevolod Borisovich
    Suarez, Cristina
    Donskov, Frede
    Pouliot, Frederic
    Alekseev, Boris Y.
    Wiechno, Pawel
    Tomczak, Piotr
    Duran, Miguel Angel Climent
    Shin, Sang Joon
    Silverman, Rachel Kloss
    Perini, Rodolfo F.
    Schloss, Charles
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [10] KEYNOTE-427 cohort B: First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (NCC-RCC).
    Lee, Jae-Lyun
    Ziobro, Marek
    Gafanov, Rustem
    Matveev, Vsevolod Borisovich
    Suarez, Cristina
    Donskov, Frede
    Pouliot, Frederic
    Alekseev, Boris Yakovlevich
    Wiechno, Pawel J.
    Tomczak, Piotr
    Climent, Miguel Angel
    Shin, Sang Joon
    Silverman, Rachel Kloss
    Perini, Rodolfo F.
    Schloss, Charles
    McDermott, David F.
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345